Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: OXA-01 is an inhibitor of both mTORC1 and mTORC2 (IC50s = 11 and 29 nM, respectively). It is selective for mTOR over PI3K isoforms and DNA protein kinase. OXA-01 reduces VEGF production in tumors in association with decreased vessel sprouting.
OXA-01 is supplied as a crystalline solid. A stock solution may be made by dissolving the OXA-01 in the solvent of choice. OXA-01 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of OXA-01 in these solvents is approximately 3 and 1 mg/ml, respectively. OXA-01 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, OXA-01 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. OXA-01 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Falcon, B.L., Barr, S., Gokhale, P.C., et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 71(5), 1573-1583 (2011).